

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number  
**WO 01/82994 A1**

- (51) International Patent Classification<sup>7</sup>: **A61L 27/38**
- (21) International Application Number: **PCT/US01/13819**
- (22) International Filing Date: **27 April 2001 (27.04.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**60/200,767** **28 April 2000 (28.04.2000)** **US**
- (71) Applicant (for all designated States except US): **CURIS, INC.** [—/US]; 61 Moulton Street, Cambridge, MA 02138 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KELLNER, Karin** [—/DE]; Karl-Stieler-Strasse 52, 93051 Regensburg (DE). **LANG, Kurt** [—/DE]; Langoner Strasse 10, 82377 Penzberg (DE). **PAPADIMITRIOU, Apollon** [—/DE]; Bachstrasse 38a, 83673 Bichl (DE). **LESER-REIFF, Ulrike** [—/DE]; Elisabethstrasse 26, 80796 Munchen (DE). **SCHULTZ, Michaela** [—/DE]; Thomas-Dehler-Weg 7, 93051 Regensburg (DE). **BLUNK, Torsten** [—/DE]; Dorfstrasse 13 c, 93080 Pentling (DE). **GOEPFERICH, Achim** [—/DE]; Enzianstrasse 5a, 93161 Sinzing (DE).
- (74) Agent: **ROPES & GRAY**; One International Place, Boston, MA 02110-2624 (US).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
  - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **METHODS AND REAGENTS FOR TISSUE ENGINEERING OF CARTILAGE IN VITRO**



Wet weight of the different cell-polymer constructs  
after 4 week culture

(57) Abstract: The present invention makes available an optimal concentration of a hedgehog polypeptide for modulating growth and/or cartilage production by chondrocytes. The present invention allows for improvements in the culturing of chondrocytes to develop cartilaginous tissue ex vivo suitable for implantation to replace damaged or deteriorated cartilage in a patient.

WO 01/82994 A1

## Methods and Reagents for Tissue Engineering of Cartilage In Vitro

### Background of the Invention

5           Cartilage is a structural tissue constructed from a variety of hydrated biopolymers. By weight, water comprises 70% to 80% of cartilage. The remaining 20% to 30% comprises extracellular biopolymers such as collagen (primarily type-II) and proteoglycan. The collagen usually accounts for 70% of the dry weight of cartilage (in "Pathology" (1988) Eds. Rubin & Farber, J. B. Lippincott Company, PA. pp.  
10   1369-1371). Proteoglycans are composed of a central protein core from which long chains of polysaccharides extend. These polysaccharides, called glycosaminoglycans, include: chondroitin-4-sulfate; chondroitin-6-sulfate; and keratan sulfate. Chondrocytes are cells responsible for the ordered production and secretion of the cartilaginous polymers. The properties of cartilage are primarily determined by the quantity and  
15   quality of the extracellular biopolymers.

          Three types of cartilage are present in mammals and include: hyaline cartilage, fibrocartilage, and elastic cartilage (Rubin and Farber, supra). Hyaline cartilage consists of a gristly mass having a firm, elastic consistency, is translucent and is pearly blue in color. Hyaline cartilage is predominantly found on the articulating surfaces of  
20   articulating joints. It is found also in epiphyseal plates, costal cartilage, tracheal cartilage, bronchial cartilage and nasal cartilage. Fibrocartilage is essentially the same as hyaline cartilage except that it contains fibrils of type I collagen that add tensile strength to the cartilage. The collagenous fibers are arranged in bundles, with the cartilage cells located between the bundles. Fibrocartilage is found commonly in the  
25   anulus fibrosus of the intervertebral disc, tendinous and ligamentous insertions, menisci, the symphysis pubis, and insertions of joint capsules. Elastic cartilage also is similar to hyaline cartilage except that it contains fibers of elastin. It is more opaque than hyaline cartilage and is more flexible and pliant. These characteristics are defined in part by the elastic fibers embedded in the cartilage matrix. Typically, elastic cartilage is present in  
30   the pinna of the ears, the epiglottis, and the larynx.

          The surfaces of articulating bones in mammalian joints are covered with articular cartilage. The articular cartilage prevents direct contact of the opposing bone

surfaces and permits the near frictionless movement of the articulating bones relative to one another (Clemente, supra).

Two types of articular cartilage defects are commonly observed in mammals and include full-thickness and partial-thickness defects. The two types of defects differ not only in the extent of physical damage but also in the nature of repair response each type of lesion elicits.

Full-thickness articular cartilage defects include damage to the articular cartilage, the underlying subchondral bone tissue, and the calcified layer of cartilage located between the articular cartilage and the subchondral bone. Full-thickness defects typically arise during severe trauma of the joint or during the late stages of degenerative joint diseases, for example, during osteoarthritis. Since the subchondral bone tissue is both innervated and vascularized, damage to this tissue is often painful. The repair reaction induced by damage to the subchondral bone usually results in the formation of fibrocartilage at the site of the full-thickness defect. Fibrocartilage, however, lacks the biomechanical properties of articular cartilage and fails to persist in the joint on a long term basis.

Partial-thickness articular cartilage defects are restricted to the cartilage tissue itself. These defects usually include fissures or clefts in the articulating surface of the cartilage. Partial-thickness defects are caused by mechanical arrangements of the joint which in turn induce wearing of the cartilage tissue within the joint. In the absence of innervation and vasculature, partial-thickness defects do not elicit repair responses and therefore tend not to heal. Although painless, partial-thickness defects often degenerate into full-thickness defects.

Repair of articular cartilage defects with suspensions of isolated chondrocytes has been attempted in a variety of animal models. See for example: Bentley, et al. (1971) *Nature* 230:385-388; Langer et al. (1974) *J. Bone Joint Surg.* 56A:297-304; Green (1977) *Clin. Orthop.* 124:237-250; and Aston et al. (1986) *J. Bone Joint Surg.* 68B:29-35). During transplantation, the cell suspensions may be retained in the defect behind a piece of periosteal tissue that has been previously attached to the surface of the normal cartilage tissue. The rate of successful implantation using cell suspensions was found to be about 40%. It is believed that chondrocytes transplanted in this manner

lose their viability during transplantation and that the procedure may result in the formation of fibrocartilage or islands of cartilage embedded in fibrous tissue at the site of the defect.

Three alternative approaches have been developed in an attempt to improve the success rate in treating mammalian articular cartilage defects. In the first approach, synthetic carrier matrices containing dispersed allogeneic chondrocytes may be implanted into the cartilage defect. The implanted chondrocytes hopefully produce and secrete components of the extracellular matrix thereby to form articular cartilage at the site of the defect in situ. In the second approach, synthetic carrier matrices containing chemotactic and mitogenic growth factors may be implanted into the cartilage defect. The growth factors hopefully induce the influx into, and the proliferation of chondrocyte progenitor cells within the matrix. The chondrocyte progenitor cells differentiate subsequently into chondrocytes that in turn secrete components of the extracellular matrix thereby to form articular cartilage at the site of the defect in situ. In the third approach, synthetic cartilage tissue may be grown in vitro and implanted subsequently into the cartilage defect.

In the first approach, the synthetic matrices or biological resorbable immobilization vehicles may be impregnated with allogeneic chondrocytes. A variety of synthetic carrier matrices have been used to date and include: three-dimensional collagen gels (U.S. Pat. No. 4,846,835; Nishimoto (1990) Med. J. Kinki University 15:75-86; Nixon et al. (1993) Am. J. Vet. Res. 54:349-356; Wakitani et al. (1989) J. Bone Joint Surg. 71B:74-80; Yasui (1989) J. Jpn. Ortho. Assoc. 63:529-538); reconstituted fibrin-thrombin gels (U.S. Pat. No. 4,642,120; U.S. Pat. No. 5,053,050 and U.S. Pat. No. 4,904,259); synthetic polymer matrices containing polyanhydride, polyorthoester, polyglycolic acid and copolymers thereof (U.S. Pat. No. 5,041,138); and polyanhydride, polyorthoester hyaluronic acid-based polymers (Robinson et al. (1990) Calcif. Tissue Int. 46:246-253); and glycosaminoglycans or dextran sulfate.

The introduction of non-autologous materials into a patient, however, may stimulate an undesirable immune response directed against the implanted material. Such an immune response has been observed in rabbit models (Yoshinaka (1990) J. Jpn. Ortho. Assoc. 64:835-846. In addition, there is evidence to suggest that neo-cartilage

may be formed around the periphery of the implant thereby preventing integration of the implant into the cartilage defect. See for example, Messner (1994) 40<sup>th</sup> Annual Meeting Orth. Res. Soc., New Orleans p. 239; and Nixon et al. (1994) 40<sup>th</sup> Annual Meeting Orth. Res. Soc., New Orleans p. 241. Monitoring the formation and  
5 development of the resulting synthetic cartilage in situ can be difficult to perform and usually involves an arthroscopic or open joint examination. Furthermore, implants containing synthetic polymer components may be unsuitable for repairing large cartilage defects since polymer hydrolysis in situ may inhibit the formation of cartilage and/or its integration into the defect.

10 In the second approach, the defect may be filled with a biocompatible, biodegradable matrix containing growth factors to stimulate the influx of chondrocyte progenitor cells into the matrix in situ. The matrices optimally contain pores of sufficient dimensions to permit the influx into, and proliferation of the chondrocyte progenitor within the matrix. The matrix also may contain differentiating growth  
15 factors to stimulate the differentiation of chondrocyte progenitor cells into chondrocytes. The resulting chondrocytes hopefully secrete extracellular matrix components thereby to form cartilage at the site of the defect in situ. See for example, U.S. Pat. No. 5,206,023; U.S. Pat. No. 5,270,300; and EP 05 30 804 A1. This approach, however, may have problems similar to those associated with the first approach, herein  
20 above.

In the third approach, chondrocytes may be cultured in vitro to form synthetic cartilage-like material. The resulting cartilage may be implanted into the cartilage defect. This type of approach has the advantage over the previous methods in that the development of the synthetic cartilage material may be monitored prior to  
25 implantation. In addition, the resulting cartilage may be characterized biochemically and morphologically prior to implantation.

In vitro tissue engineering of cartilage on a polymer matrix is problematic because the resultant cell-polymer construct often has properties that are unfavorable for successful grafting. Particularly, the quantity and quality of secreted polymers does  
30 not adequately mimic that found in natural cartilage. Typically the amount of

proteoglycan and collagen (measured relative to cell number or to total wet weight of the cell-polymer construct) is lower than in natural cartilage.

It has previously been demonstrated that hedgehog polypeptides (including hydrophobically-modified hedgehog polypeptides) have trophic effects on  
5 chondrocytes both in vivo and in vitro. (Iwasaki, Jikko & Le, 1999, Br. J Bone Joint Sur. 81, 1076; Iwanoto, et al., 1999, Crit Rev. Oral Biol. Med. 10, 477-86.). U.S. Patent No. 5,972,385 suggests, but does not exemplify, the use of a oxidized polysaccharide matrix for the induction of connective tissue, including cartilage, which matrix is loaded with collagen and may be optionally loaded with a growth factor such  
10 as a hedgehog protein by co-valent linkage. The reference patent does not suggest for which type of connective tissue the use of a hedgehog protein is appropriate.

It would be advantageous to identify whether and in what optimal amounts of hedgehog polypeptides can be used to produce in vitro by culturing of chondrocytes in vitro a cartilage better adapted for implantation.

15

### **Summary of the Invention**

In-vitro tissue engineering of cartilage using biodegradable three-dimensional polymer meshes is one approach to solve the medical problems associated with  
20 defective cartilage due to trauma, congenital abnormalities or arthritis (Freed, LE, 1995, in: The Biomedical Engineering Handbook, CRC Press, 1788-1806). To improve the properties of the tissue developed in tissue engineering, the addition of exogenous growth factors can be useful (Gooch et al., 1998, Frontiers of Tissue Engineering, Pergamon 68-73).

25 The present invention discloses the use of a hedgehog therapeutic as a trophic factor in the tissue-culture production of cartilage for implantation. The invention further discloses the use of hydrophobically-modified hedgehog proteins for this purpose. One aspect of the present invention is the use of optimal concentrations of hydrophobically-modified hedgehog proteins in the range of about 500-1000 ng/ml of  
30 dipalmitoyl sonic hedgehog.

### **Brief Description of the Drawings**

Figure 1: Wet weight of the different cell-polymer constructs after 4 week culture.

5        Figure 2: Proteoglycan content per wet weight of the different cell-polymer constructs after 4 week culture.

Figure 3: Safranin O staining of grown tissue cultured without (left) and with 10000 ng/ml of hydrophobically modified sonic hedgehog protein.

10

### **Detailed Description of the Invention**

#### **I. Overview**

The present invention makes available an optimal concentration of a hedgehog polypeptide for modulating growth and/or cartilage production by chondrocytes. The present invention allows for improvements in the culturing of chondrocytes to develop  
15        cartilaginous tissue ex vivo suitable for implantation to replace damaged or deteriorated cartilage in a patient.

#### **II. Definitions**

20        For convenience, certain terms employed in the specification, examples, and appended claims are collected here.

An "effective amount" of, e.g., a therapeutic compound, with respect to the subject method of treatment, refers to an amount of the compound in a preparation which, when applied as part of a desired dosage regimen brings about a desirable  
25        response according to clinically acceptable standards for the disorder to be treated.

The "growth state" of a cell refers to the rate of proliferation of the cell and/or the state of differentiation of the cell. An "altered growth state" is a growth state characterized by an abnormal rate of proliferation, e.g., a cell exhibiting an increased or decreased rate of proliferation relative to a normal cell.

30        The term "*hedgehog* therapeutic" refers to various forms of *hedgehog* polypeptides, as well as peptidomimetics, which can modulate the

proliferation/differentiation state of chondrocytes directly or indirectly. For instance, the *hedgehog* therapeutic may interact chondrocytes or progenitors thereof to effect their proliferative state. The *hedgehog* therapeutic may also function by inducing or inhibiting, as will be clear from the context of individual examples, expression of a parathyroid hormone-related protein. The term includes naturally occurring forms of *hedgehog* proteins, as well as modified or mutant forms generated by molecular biological techniques, chemical synthesis, etc. While in preferred embodiments the *hedgehog* polypeptide is derived from a vertebrate homolog, cross-species activity reported in the literature supports the use of *hedgehog* polypeptides from invertebrate organisms as well. Naturally and non-naturally occurring *hedgehog* therapeutics referred to herein as "agonists" mimic or potentiate (collectively "agonize") the effects of a naturally-occurring *hedgehog* protein on bone formation, chondrocyte proliferation, etc. In addition, the term "hedgehog therapeutic" includes molecules which can activate expression of an endogenous *hedgehog* gene. The term also includes gene therapy constructs for causing expression of *hedgehog* polypeptides *in vivo*, as for example, expression constructs encoding recombinant *hedgehog* polypeptides as well as trans-activation constructs for altering the regulatory sequences of an endogenous *hedgehog* gene by homologous recombination

In particular, the term "*hedgehog* polypeptide" encompasses preparations of *hedgehog* proteins and peptidyl fragments thereof, both agonist and antagonist forms as the specific context will make clear.

"Homology" and "identity" each refer to sequence similarity between two polypeptide sequences, with identity being a more strict comparison. Homology and identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same amino acid residue, then the polypeptides can be referred to as identical at that position; when the equivalent site is occupied by the same amino acid (e.g., identical) or a similar amino acid (e.g., similar in steric and/or electronic nature), then the molecules can be referred to as homologous at that position. A percentage of homology or identity between sequences is a function of the number of matching or homologous positions shared by the sequences. An "unrelated" or "non-homologous"



sequence shares less than 40 percent identity, though preferably less than 25 percent identity, with a hedgehog sequence of the present invention.

The term "hydrophobically-modified hedgehog polypeptide" refers to any hedgehog polypeptide that is covalently attached to one or more lipophilic molecules.

5 A standard definition of a lipophilic molecule is one with poor solubility in pure water. Examples of lipophilic molecules are given below.

A "patient" or "subject" to be treated by the subject method can mean either a human or non-human animal, such as a mammal.

As used herein, "proliferating" and "proliferation" refer to cells undergoing  
10 mitosis.

### III. Exemplary Applications of Method and Compositions

The present invention makes available an optimal concentration of a hydrophobically-modified hedgehog polypeptide for promoting cartilage production in  
15 vitro. Such methods are useful in, for example, the production of three-dimensional cartilage grafts to repair defects or lesions in cartilage tissue. The defects or lesions may result from degenerative wear such as that which results in arthritis, as well as other mechanical derangements which may be caused by trauma to the tissue, such as a displacement of torn meniscus tissue, meniscectomy, a taxation of a joint by a torn  
20 ligament, malignment of joints, bone fracture, or by hereditary disease.

The subject method can be applied to enhancing the generation of prosthetic cartilage devices. The need for improved treatment has motivated research aimed at creating new cartilage that is based on collagen-glycosaminoglycan templates (Stone et al. (1990) Clin Orthop Relat Res 252:129), isolated chondrocytes (Grande et al. (1989) J Orthop Res 7:208; and Takigawa et al. (1987) Bone Miner 2:449), and chondrocytes  
25 attached to natural or synthetic polymers (Walitani et al. (1989) J Bone Jt Surg 71:74; Vacanti et al. (1991) Plast Reconstr Surg 88:753; von Schroeder et al. (1991) J Biomed Mater Res 25:329; Freed et al. (1993) J Biomed Mater Res 27:11; and the Vacanti et al. U.S. Pat. No. 5,041,138). For example, chondrocytes can be grown in  
30 culture on biodegradable, biocompatible highly porous scaffolds formed from polymers such as polyglycolic acid, polylactic acid, agarose gel, or other polymers

which degrade over time as function of hydrolysis of the polymer backbone into innocuous monomers. The matrices are designed to allow adequate nutrient and gas exchange to the cells until engraftment occurs. The cells can be cultured in vitro until adequate cell volume and density has developed for the cells to be implanted. One  
5 advantage of the matrices is that they can be cast or molded into a desired shape on an individual basis, so that the final product closely resembles the patient's own ear or nose (by way of example), or flexible matrices can be used which allow for manipulation at the time of implantation, as in a joint. In one embodiment of the subject method, chondrocytes are seeded into a polymeric matrix. The matrix may be  
10 composed of one or more of the following: polyglycolid acid, collagen, dextran sulfate, polyanhydride, polyorthoester, hyaluronic acid-based polymers, or glycosaminoglycans. The cell-polymer constructs are contacted with an optimal concentration of a hydrophobically-modified hedgehog polypeptide. The optimal concentration is preferably more than 500 ng/ml, more preferably more than 800  
15 ng/ml, more preferably approximately 1000 ng/ml, and most preferably 1000 ng/ml. In this manner the production of secreted polymers such as proteoglycans and collagens is increased, as is the overall wet weight of the construct. Additionally, the chondrocytes become larger and there is more space between chondrocytes within the cell-polymer construct.

20 There are a wide range of lipophilic moieties with which hedgehog polypeptides can be derivatized. The term "lipophilic group", in the context of being attached to a hedgehog polypeptide, refers to a group having high hydrocarbon content thereby giving the group high affinity to lipid phases. A lipophilic group can be, for example, a relatively long chain alkyl or cycloalkyl (preferably n-alkyl) group having  
25 approximately 7 to 30 carbons. The alkyl group may terminate with a hydroxy or primary amine "tail". To further illustrate, lipophilic molecules include naturally-occurring and synthetic aromatic and non-aromatic moieties such as fatty acids, esters and alcohols, other lipid molecules, cage structures such as adamantane and buckminsterfullerenes, and aromatic hydrocarbons such as benzene, perylene,  
30 phenanthrene, anthracene, naphthalene, pyrene, chrysene, and naphthacene.

Particularly useful as lipophilic molecules are alicyclic hydrocarbons, saturated and unsaturated fatty acids and other lipid and phospholipid moieties, waxes, cholesterol, isoprenoids, terpenes and polyalicyclic hydrocarbons including adamantane and buckminsterfullerenes, vitamins, polyethylene glycol or oligoethylene glycol, (C 1-C 18)alkyl phosphate diesters, -O-CH<sub>2</sub>-CH(OH)-O-(C<sub>12</sub>-C<sub>18</sub>)-alkyl, and in particular conjugates with pyrene derivatives. The lipophilic moiety can be a lipophilic dye suitable for use in the invention include, but are not limited to, diphenylhexatriene, Nile Red, N-phenyl-1-naphthylamine, Prodan, Laurodan, Pyrene, Perylene, rhodamine, rhodamine B, tetramethylrhodamine, Texas Red, sulforhodamine, 1,1'-didodecyl3,3',3'tetramethylindocarbocyanine perchlorate, octadecyl rhodamine B and the BODIPY dyes available from Molecular Probes Inc.

Other exemplary lipophilic moieties include aliphatic carbonyl radical groups include 1- or 2-adamantylacetyl, 3-methyladamant-1-ylacetyl, 3-methyl-3-bromo-1-adamantylacetyl, 1-decalinacetyl, camphoracetyl, camphaneacetyl, noradamantylacetyl, norbornaneacetyl, bicyclo[2.2.2.]-oct-5-eneacetyl, 1-methoxybicyclo[2.2.2.]-oct-5-ene-2-carbonyl, cis-5-norbornene-endo-2,3-dicarbonyl, 5-norbornene-2-ylacetyl, (1R)-(-)-myrtenaneacetyl, 2-norbornaneacetyl, anti-3-oxo-tricyclo[2.2.1.0<2,6>]-heptane-7-carbonyl, decanoyl, dodecanoyl, dodecenoyl, tetradecadienoyl, decynoyl or dodecynoyl.

### **Exemplification**

The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.

### **Effects of Hedgehog Proteins on Tissue Engineering of Cartilage In Vitro.**

**Materials:****Chondrocytes:**

Bovine articular chondrocytes were isolated from the femoropatellar groove of 6 week-old calves. Cells were isolated and cultivated as previously described (5).

5

**Polymer scaffolds:**

The chondrocytes were cultured on PGA (polyglycolid acid) scaffolds. The scaffolds were produced at Albany International (Mansfield, MA) by extruding PGA into 13 um-diameter fibers and processing these into fibrous discs measuring 5 mm in diameter x 2 mm in thickness (bulk density of 43 mg/cm').

10

**Proteins:**

As sonic hedgehog (shh) is found to be tethered to cell membranes for example in a form that contains a palmitoyl group (6) dipalmitylated sonic hedgehog (dp-shh), dipalmitylated indian hedgehog (dp-ihh) and sonic hedgehog dimer (shh-dimer) were used in varying concentrations supplemented to the culture medium.

15

**Method:****Cell culture:**

Isolated chondrocytes were seeded onto the scaffolds in a spinner-flask for two days at 80 rpm in an incubator at 37°C, 5% CO<sub>2</sub> and 95 % humidity. Each scaffold was then placed in a 6-well plate in 6 ml culture medium containing 1% FBS and put on an orbital shaker at 50 rpm. After two days the culture medium was changed and from this time point the effector molecules were added in varying concentrations with each medium change. Medium was replaced 3 times per week for up to 4 weeks.

20

25

**Assessment of tissue quality:**

Directly after harvesting the constructs were weighed (=wet weight) and cut in halves. One part was prepared as histological sample (safranin-O staining for proteoglycan and immunohistological collagen type II staining), the other part was used for biochemical analysis. Therefore this part was freeze-dried, digested overnight

30

with papainase and then analyzed for cell number, content of total collagen and proteoglycan content of the cell-polymer construct (5).

### Results and Discussion:

5        After four weeks a dose-dependent increase in wet weight (Fig. 1), tissue size and mechanical resistance (Fig. 1), tissue size and mechanical resistance was detected for all cell-polymer constructs receiving hedgehog proteins, with dip almitoyl-sonic hedgehog at  $c = 1000$  ng/ml showing the largest response.

10        Collagen amount generally increased proportionally with increasing construct weight. Collagen type tI as marker for differentiated chondrocytes was detected in abundance in all samples.

15        A great concentration-dependent influence on proteoglycan content was determined for all hedgehog proteins (Fig. 2). Proteoglycan content increased to an even larger extend than the wet weight of the constructs, thus leading to an improved biochemical composition of the tissue. Dipalmityl-sonic hedgehog showed the largest effects of all at  $c = 1000$  ng/ml (2.7 fold increase compared to control constructs receiving no exogenous hedgehog protein).

20        Additionally the cell number per wet weight decreased with increasing hedgehog concentrations. Taken together with the increased cumulated amounts of proteoglycan and collagen the data suggested an increased ECM production for each cell.

25        In general hedgehog proteins led to a higher proteoglycan content, a more equivalent distribution of proteoglycan and in addition a more mature tissue with bigger and a lower number of cells in the cell-polymer construct (exemplarily shown in Fig. 3).

### Conclusion:

30        All three different modified hedgehog proteins showed a positive effect on tissueengineered cartilage, with the dipalmitylated sonic hedgehog (at  $c = 1000$  ng/ml) showing the greatest effect of all. Thus this molecule may be a candidate for use, also

in combination with other growth factors, in tissue engineering of cartilage to improve the development and biochemical composition of engineered tissue.

**References:**

- 5 (1) L.E. Freed, G. Vunjak-Novakovic, in: The Biomedical Engineering Handbook, CRC Press (1995) 1788-1806.
- (2) K. Gooch, et al. In: Frontiers of Tissue Engineering, Pergamon (1998) 68-73.
- (3) H.M. Kronenberg, et al. J. Endocrinol. 154 (1997) 39-45.
- (4) A. Vortkamp, et al. Mech. Dev. 71 (1998) 65-76,
- 10 (5) L.E. Freed, et al J. Biomed. Mater. Res. 27 (1993) 11-23.
- (6) R.B. Pepinsky, et al. J. Biol. Chem. 273 (1998) 14037-14045.

**Equivalents**

15 Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

This application hereby incorporates by reference U.S. Provisional Application  
20 No. 60/200,767, Filed April 28, 2000.

What is claimed:

1. A method of making a cartilaginous prosthesis comprising seeding a polymeric matrix construct with chondrocytes and contacting the seeded construct with a hedgehog therapeutic.
- 5 2. The method of claim 1, wherein the chondrocytes are articular chondrocytes.
3. The method of claim 2, wherein the hedgehog therapeutic is a naturally-occurring hedgehog polypeptide.
- 10 4. The method of claim 2, wherein the hedgehog therapeutic is a hydrophobically-modified hedgehog polypeptide.
- 15 5. The method of claim 3, wherein the hydrophobically modified hedgehog polypeptide is di-palmitoyl sonic hedgehog or dipalmitoyl indian hedgehog.
6. The method of claim 4, wherein the seeded construct is contacted with di-palmitoyl hedgehog at a concentration of at least 500 ng/ml.
- 20 7. The method of claim 4, wherein the seeded construct is contacted with di-palmitoyl sonic hedgehog at a concentration of between 500 and 1000 ng/ml.
8. The method of claim 1, wherein the polymeric matrix is selected from the group consisting of polyglycolid acid, collagen, dextran sulfate, polyanhydride, polyorthoester, hyaluronic acid-based polymers, and a glycosaminoglycan.
- 25 9. The method of claim 6, wherein the polymeric matrix is polycolid acid.
- 30 10. A tissue culture system for the production of cartilage comprising a polymeric matrix, chondrocytes adherent to the matrix and a culture medium comprising an amount of a hedgehog therapeutic sufficient to cause an increase in the

proteoglycan content of the cartilage, compared to the content in absence of the hedgehog therapeutic.

11. The tissue culture system of claim 10, in which the hedgehog therapeutic is a  
5 naturally occurring hedgehog polypeptide.
12. The tissue culture system of claim 11, in which the hedgehog polypeptide is sonic hedgehog or indian hedgehog.
- 10 13. The tissue culture system of claim 10, in which the hedgehog therapeutic is a hydrophobically modified hedgehog polypeptide.
14. The tissue culture system of claim 13, in which the hedgehog therapeutic is dipalmitoyl sonic hedgehog or dipalmitoyl indian hedgehog.  
15
15. The tissue culture system of claim 14, in which the amount of the hedgehog therapeutic is between 500 and 1000 ng/ml.






FIGURE 1




Fig.2: Proteoglycan content per wet weight of the different cell-polymer constructs after 4 week culture

FIGURE 2




Fig.3: Safranin O staining of grown tissue cultured without (left) and with shh c = 10000ng/ml (right)

FIGURE 3

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/13819

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L27/38

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, COMPENDEX, BIOSIS, CHEM ABS Data, MEDLINE, EMBASE, SCISEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 978 285 A (HOFFMANN LA ROCHE) 9 February 2000 (2000-02-09) paragraphs '0015!', '0022!', '0024! examples 2,3 claims 1,7-11	1-15
Y	WO 95 33821 A (ADVANCED TISSUE SCIENCES INC) 14 December 1995 (1995-12-14) abstract examples claims 1,2	1-15
A	US 5 972 385 A (LIU LINSHU ET AL) 26 October 1999 (1999-10-26) cited in the application claims 1,2,15	1-15
	--- -/-- ---	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

27 September 2001

Date of mailing of the international search report

05/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Muñoz, M

## INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 01/13819

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	EP 1 025 861 A (ROCHE DIAGNOSTICS GMBH) 9 August 2000 (2000-08-09) paragraphs '0014!, '0024!, '0026!, '0027! -----	1-15

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/13819

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0978285	A	09-02-2000	EP 0987028 A1	22-03-2000
			EP 0978285 A1	09-02-2000
			AU 4344899 A	02-03-2000
			BR 9903555 A	19-09-2000
			CN 1244429 A	16-02-2000
			HR 990244 A1	30-04-2000
			HU 9902655 A2	28-08-2000
			JP 2000063283 A	29-02-2000
			NO 993804 A	08-02-2000
			PL 334797 A1	14-02-2000
			TR 9901897 A2	21-03-2000
			US 6207718 B1	27-03-2001
WO 9533821	A	14-12-1995	US 5902741 A	11-05-1999
			AU 689605 B2	02-04-1998
			AU 2769695 A	04-01-1996
			CA 2192064 A1	14-12-1995
			EP 0812351 A1	17-12-1997
			NZ 288467 A	28-10-1998
			WO 9533821 A1	14-12-1995
			US 5962325 A	05-10-1999
			US 6140039 A	31-10-2000
			US 6022743 A	08-02-2000
			US 5863531 A	26-01-1999
US 5972385	A	26-10-1999	US 5866165 A	02-02-1999
			AU 727430 B2	14-12-2000
			AU 5920398 A	07-08-1998
			EP 0994694 A1	26-04-2000
			JP 2000514698 T	07-11-2000
			WO 9831345 A1	23-07-1998
EP 1025861	A	09-08-2000	EP 1025861 A1	09-08-2000
			AU 2441200 A	25-08-2000
			WO 0045848 A1	10-08-2000